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AbstrAct
The tumor microenvironment is critical to cancer growth and therapy resistance. 
We previously characterized human ovarian carcinoma-associated mesenchymal stem 
cells (CA-MSCs). CA-MSCs are multi-potent cells that can differentiate into tumor 
microenvironment components including fibroblasts, myofibroblasts and adipocytes. 
We previously reported CA-MSCs, compared to normal MSCs, express high levels of 
BMP proteins and promote tumor growth by increasing numbers of cancer stem-
like cells (CSCs). We demonstrate here that ovarian tumor cell-secreted Hedgehog 
(HH) induces CA-MSC BMP4 expression. CA-MSC-derived BMP4 reciprocally increases 
ovarian tumor cell HH expression indicating a positive feedback loop. Interruption of 
this loop with a HH pathway inhibitor or BMP4 blocking antibody decreases CA-MSC-
derived BMP4 and tumor-derived HH preventing enrichment of CSCs and reversing 
chemotherapy resistance. The impact of HH inhibition was only seen in CA-MSC-
containing tumors, indicating the importance of a humanized stroma. These results 
are reciprocal to findings in pancreatic and bladder cancer, suggesting HH signaling 
effects are tumor tissue specific warranting careful investigation in each tumor type. 
Collectively, we define a critical positive feedback loop between CA-MSC-derived BMP4 
and ovarian tumor cell-secreted HH and present evidence for the further investigation 
of HH as a clinical target in ovarian cancer.
IntroductIon
Ovarian cancer is the most deadly US gynecologic 
malignancy, killing over 14,000 women yearly [1]. Most 
ovarian cancer cases are diagnosed as late stage disease 
with diffuse peritoneal metastasis indicating an ovarian 
cancer tropism for the intra-abdominal microenvironment. 
Despite initial chemotherapeutic response, most ovarian 
cancer patients will develop recurrent disease. Inevitably, 
recurrent disease will become resistant to standard 
platinum-based chemotherapy ultimately leading to patient 
death. The tumor microenvironment is critical for the 
growth, spread and survival of cancer cells with emerging 
data describing the importance of stromal components 
such as adipocytes and cancer associated fibroblasts in 
ovarian cancer [2-5]. 
Mesenchymal stem cells (MSCs) are an important 
component of the tumor microenvironment [6, 7]. MSCs 
were first characterized from bone marrow, adipose and 
embryonic tissues and are well-documented to travel to 
tumor sites [8-10]. MSCs have now been reported in a 
variety of other tissues including ovary, brain, spleen, 
liver, kidney, lung, muscle, thymus, pancreas, eyelid, and 
the peri-vasculature [11-13], suggesting MSCs may be 
present in many tissues throughout tumor initiation and 
growth. 
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Recently our lab isolated primary human ovarian 
carcinoma-associated MSCs (CA-MSCs) [14]. CA-
MSCs are distinct from cancer associated fibroblasts; 
CA-MSCs meet all the established criteria for MSCs 
[15] with appropriate surface marker expression and 
multipotent differentiation potential. As a multi-
potent stem cell population, CA-MSCs (unlike cancer 
associated fibroblasts) will passage for many months in 
culture. CA-MSCs have a normal genome and do not 
form tumors [16]. However, CA-MSCs are strongly 
pro-tumorigenic, increasing both tumor growth and 
“stemness” [14]. Importantly, as CA-MSCs are multi-
potent cells capable of differentiating into several critical 
components of the tumor stroma including fibroblasts, 
osteocytes and adipocytes [15], therapeutic targeting of 
CA-MSCs could impact multiple components of the tumor 
microenvironment and thereby have a powerful anti-tumor 
effect. 
CA-MSCs have a unique expression profile 
compared to normal adipose, bone marrow or ovary 
derived MSCs characterized by increased BMP expression 
(particularly BMP2 and BMP4) [14, 16]. The factors 
leading to the unique expression profile of CA-MSCs are 
unknown; however our previous work suggests that tumor-
secreted factors contribute to the CA-MSC expression 
profile. 
One potential tumor derived CA-MSC regulating 
factor is Hedgehog (HH). HH signaling, which is critical 
during development and in maintenance of the adult stem 
cell pool, is a key regulator of BMP expression [17]. 
HH signaling also has emerging roles in tumor/stromal 
signaling [18]. In ovarian cancer, increased HH signaling 
is correlated with poor outcomes [19] and HH signaling 
is increased in ovarian cancer at the time of disease 
recurrence [20]. HH appears to be particularly important 
in the tumor microenvironment as HH signaling in ovarian 
tumor stroma is associated with enhanced chemoresistance 
and decreased survival [3, 19, 21]. In contrast, HH 
signaling appears to restrict tumor progression in bladder 
cancer and HH inhibition produced negative clinical 
results in pancreatic cancer. These contrasting results 
highlight the complexity of the HH pathway and may 
indicate tissue specific effects of HH signaling which 
would be unsurprising given the divergent effects of HH 
in spatiotemporal gradients during development [22, 23].
We investigated a possible role for HH signaling in 
CA-MSCs. We demonstrate that tumor-derived HH drives 
CA-MSC BMP4 production. CA-MSC-derived BMP4 
reciprocally increases HH production in ovarian cancer 
cells thus creating a positive feedback loop between 
the tumor and CA-MSCs. This feedback loop promoted 
chemotherapy resistance both in vitro and in vivo. In 
vivo pharmacologic HH inhibition abrogated the pro-
tumorigenic effects of CA-MSCs preventing increases in 
cancer stem cell-like cell (CSC) percentage and reversed 
chemotherapy resistance indicating that HH signaling is 
critical for the tumor growth promoting function of CA-
MSCs.
results
Hedgehog signaling is active in the stroma of 
normal ovary and ovarian cancer
To explore the role of HH signaling in the ovarian 
cancer microenvironment we first confirmed HH 
signaling in normal ovarian tissue and ovarian tumors. 
To confirm HH activity in normal ovaries and ovarian 
tumors we used a Gli1lacZ reporter mouse [24, 25]. Gli1 
is both a downstream component of HH signaling and a 
transcriptional target, thus its expression indicates pathway 
activation [26]. We observed strong Beta-Galactosidase 
(β-Gal) activity throughout the normal murine ovarian 
stroma (Figure 1Ai). β-Gal expression was not observed 
in the ovarian surface epithelium, in developing follicles, 
or in the epithelial lining of the oviduct (the murine 
equivalent of the fallopian tube). β-Gal expression was 
detected in the peri-vasculature; a reported location for 
tissue associated MSCs [12]. 
To determine if HH signaling is active in ovarian 
tumor stroma, we transplanted ID8 mouse ovarian tumor 
cells into the flank of Gli1lacZ mice. β-Gal as an indicator 
of HH signaling was clearly noted within the tumor stroma 
with significantly less β-Gal in adjacent non-tumor stroma 
(Figure 1Aii, iii). To confirm HH signaling in human 
ovarian cancer, qRT-PCR of cDNA generated from 
primary human ovarian tumor samples were analyzed. 
Consistent with previous results [27], GLI1 and GLI3 (HH 
pathway transcriptional effectors), PTCH1 (HH signaling 
repressor and target gene), SMO (HH signaling activator), 
IHH and SHH (HH pathway ligands) were expressed in 
ovarian tumors, albeit at variable levels (Figure 1B). 
Mesenchymal stem cells respond to HH ligands 
produced by ovarian cancer cells
Given the largely stromal localization of HH 
pathway activation, we next explored the ability of MSCs 
to respond to HH signaling. We tested the ability of both 
normal ovary derived MSCs (Ov-MSCs) and, given the 
predilection of ovarian cancer for omental adipose, normal 
adipose derived MSCs (A-MSCs) to respond to HH. 
A-MSCs and Ov-MSCs treated with recombinant Sonic 
Hedgehog (SHH) demonstrated increased expression 
of downstream targets of the canonical HH pathway 
indicating both MSC groups respond to HH signaling 
(Figure 1C, 1D). CA-MSCs also demonstrated clear 
response to HH treatment with induction of GLI1, SMO, 
PTCH1 and GAS1 (Figure 1D).
To determine if cancer cells are a source of HH 
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ligands, we treated CA-MSCs with conditioned media 
from multiple ovarian cancer cell lines or primary 
human ovarian cancer cell cultures. The induction of 
HH responsive genes was analyzed via qRT-PCR. Tumor 
conditioned media (TCM) lead to a similar pattern of 
HH target gene induction as seen with recombinant 
SHH (Figure 1E). This suggests that ovarian cancer 
cells produce HH ligands that can activate HH signaling 
pathways in MSCs. 
tumor-derived HH differentially induces the 
expression of bMP4 in cA-Mscs
Given (i) the responsiveness of MSCs to HH 
signaling, (ii) the role of HH in regulating BMP expression 
[17], and (iii) the differential expression of BMPs in 
CA-MSCs compared to normal controls, we assessed if 
HH activation could be the etiology of increased BMP 
Figure 1: HH signaling is active in the normal ovary, ovarian tumor stroma and in Mscs. A. Gli1-LacZ reporter mice 
demonstrate Gli1 expression (blue) in i) normal ovary stroma, and ii) ID8 ovarian tumor stroma with iii) quantification of Gli1-LacZ 
positive area in tumor stroma vs non-tumor stroma demonstrating significantly higher levels in tumor stroma (quantification via ImageJ 
analysis in 3 tumor and non-tumor sections). b. qRT-PCR analysis of GLI1, GLI3, SMO, PTCH, IHH and SHH in primary ovarian tumors 
confirming HH signaling components are expressed in all tumors tested. c. SHH treatment of normal adipose derived MSCs demonstrate 
dose dependent activation of the canonical HH signaling pathway (data are normalized to untreated adipose MSC GLI1 value). d. qRT-PCR 
demonstrating treatment of A-MSCs, normal ovary (Ov-MSCs) and CA-MSCs with recombinant SHH activates HH signaling pathway. 
e. qRT-PCR demonstrating tumor conditioned media (TCM) likewise activates HH signaling in CA-MSCs. Error bars=standard error of 
the mean.
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signaling in CA-MSCs. qRT-PCR analysis confirmed 
greater baseline expression of BMP2 and BMP4 in CA-
MSCs compared to normal Ov-MSCs and A-MSCs (data 
not shown and Figure 2A). HH treatment of A-MSCs 
and Ov-MSCs did not result in a significant (0-2.8 fold) 
induction of either BMP2 or BMP4 (Supplemental Figure 
1 and Figure 2B). However, treatment of CA-MSCs with 
HH led to significant induction (5-30 fold) of BMP4 
(Figure 2B). BMP2 expression was modestly increased in 
CA-MSCs (Supplemental Figure 1). 
Given the HH-mediated induction of BMP4 in 
CA-MSCs, we investigated if tumor derived HH could 
likewise induce BMP4 expression. CA-MSCs were 
treated with TCM from three human ovarian cancer cell 
lines (SKOV3, COV318, CAOV-3). BMP4 expression 
was increased in response to treatment with all three TCM 
(Figure 2C). Treatment with IPI-926, a SMO inhibitor, 
significantly decreased the TCM-mediated induction of 
BMP4 transcription (Figure 2C) and BMP4 protein levels 
(Figure 2D) suggesting activation of BMP4 expression is 
via tumor cell produced HH ligands. 
A paracrine HH-bMP4 ovarian cancer cell-cA-
Msc positive feedback loop
We previously showed that CA-MSC-derived BMP 
directly impacts ovarian cancer cells [14]. We therefore 
hypothesized that CA-MSC-derived BMP4 may alter HH 
expression in tumor cells though a feedback mechanism. 
To investigate this possibility, we treated ovarian cancer 
cells with recombinant BMP4 and analyzed SHH 
expression via qRT-PCR. SHH expression was increased 
in SKOV3 and CAOV-3 cell lines after 48hrs of BMP4 
treatment (Figure 3A). This induction was seen at 
both early (16hr) and later (48hr) time points (data not 
Figure 2: cA-Mscs respond to tumor derived HH with increased bMP4. A. qRT-PCR analysis of BMP4 expression in 
normal adipose MSCs (A-MSC1,2,3), normal ovary MSCs (Ov-MSC) and patient derived CA-MSCs (CA-MSC 1-4) demonstrating higher 
baseline BMP4 expression in CA-MSCs, relative expression compared to A-MSC3. b. qRT-PCR analysis of BMP4 expression in A-MSC, 
Ov-MSC and CA-MSCs without and with SHH demonstrating SHH-mediated BMP4 induction in CA-MSCs (expression is normalized 
to untreated controls for each pair). c. qRT-PCR analysis of BMP4 expression in CA-MSCs demonstrating that tumor conditioned media 
(TCM) derived from 3 ovarian cancer cell lines induces BMP4 expression and this induction can be blocked by the HH inhibitor IPI-926, 
all samples normalized to CA-MSC without IPI-926. d. Western blot of BMP4 protein levels in CA-MSCs ± TCM with or without IPI-926. 
Error bars=standard error of the mean.
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shown) indicating that BMP4 treatment is not selecting 
for a population of cells with higher SHH expression 
but inducing a general increase in SHH expression. In 
the COV318 ovarian cancer cell line, BMP4 treatment 
induced IHH rather than SHH (Figure 3B). HH induction 
was verified at the protein level via western blot (Figure 
3C). The reciprocal induction of tumor derived HH 
by BMP4 creates a possible signaling loop with tumor 
derived HH and CA-MSC derived BMP4.To investigate 
the possibility of this positive feedback loop, we next 
utilized a transwell system for co-culture of CA-MSCs 
and ovarian tumor cells. The transwell membrane allowed 
Figure 3: ovarian tumor cells respond to bMP4 with increased HH forming a positive feedback loop interrupted 
by HH inhibition. A. qRT-PCR analysis of ovarian cancer lines SKOV3 and CAOV-3 treated with BMP4 (200ng/ml) demonstrates 
induction of SHH. b. qRT-PCR analysis of ovarian cancer line COV318 treated with BMP4 demonstrates induction of IHH. c. Induction 
of SHH was verified at the protein level via western blot. d. qRT-PCR analysis of CA-MSCs grown in co-culture with tumor cell lines 
(SKOV3, CAOV-3 and COV318) for 5 days ± IPI-926 demonstrates BMP4 induction which is abrogated by IPI-926. e. i) qRT-PCR 
analysis of SKOV3 and CAOV-3 cells grown in co-culture with CA-MSCs demonstrate tumor SHH induction blocked by IPI-926, ii) 
qRT-PCR analysis of COV318 cells demonstrate IHH induction with CA-MSC co-culture decreased by IPI-926. F. qRT-PCR analysis of 
average BMP4 expression of CA-MSCs grown in co-culture with SKOV3 or CAOV-3 cells demonstrating decreased BMP4 induction with 
the SMO inhibitor LDE225 or a BMP4 blocking antibody. G. qRT-PCR analysis of average SHH induction of SKOV3 or CAOV-3 cells 
co-cultured with CA-MSCs demonstrating decreased SHH induction with LED225 or a BMP4 blocking antibody. Error bars=standard error 
of the mean.
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only indirect cell/cell contact therefore interactions 
based on secreted factors were assessed. Cells were co-
cultured for 5 days ± IPI-926. Cells were harvested from 
their respective chambers (CA-MSCs in the upper well, 
tumor cells in the lower well) and analyzed via qRT-
PCR to determine levels of BMP4 in CA-MSCs and HH 
in tumor cells. Co-culture resulted in clear induction of 
BMP4 in CA-MSCs that was decreased in the presence 
of IPI-926 (Figure 3D). Likewise, SKOV3 and CAOV-
3 tumor cells demonstrated significant induction of SHH 
while COV318 cells demonstrated significant induction 
of IHH (Figure 3E). IPI-926 diminished both SHH and 
IHH induction though effects on IHH induction were more 
modest (Figure 3Eii). IPI-926 treatment of CA-MSCs 
grown in single culture did not affect BMP4 expression 
levels or cellular viability. Analogously, IPI-926 treatment 
of tumor cells grown alone had no effect on tumor cell 
HH expression or cellular viability (Supplemental Figure 
2). Similarly, another SMO inhibitor, LDE-225, and 
a BMP4 blocking antibody were used in the co-culture 
system (with SKOV3 and CAOV-3 tumor cells) and both 
demonstrated a reduction in CA-MSC derived BMP4 and 
tumor derived HH (Figure 3F, 3G). These findings indicate 
a tumor/MSC HH/BMP4 signaling loop. 
Inhibition of HH signaling blocks the pro-
tumorigenic effects of cA-Mscs
We previously demonstrated that CA-MSCs 
significantly promote tumor growth in a BMP2/4-
dependent manner. We therefore investigated whether 
disruption of the HH:BMP4 signaling loop with a HH 
inhibitor could alter the pro-tumorigenic effects of CA-
MSCs. We created xenografts using SKOV3 cells alone, 
SKOV3 + A-MSCs and SKOV3 + CA-MSCs. Mice were 
treated with IPI-926 (20mg/kg daily via IP injection for 21 
days) or vehicle control. Mice were sacrificed when tumor 
volumes reached size criteria or treatment was complete. 
Consistent with our previous report [14], untreated 
SKOV3+CA-MSC tumors grew significantly faster than 
SKOV3+A-MSC or SKOV3 alone tumors (Figure 4A and 
Supplemental Figure 3A). Surprisingly, IPI-926 treatment 
completely abolished the growth advantage provided by 
CA-MSCs (Figure 4A and Supplemental Figure 3B). IPI-
926 had no effect on the growth of SKOV3 alone tumors, 
highlighting a critical role of human CA-MSCs in HH 
mediated tumorigenesis (Figure 4A).
Confirming on-target effects of IPI-926, western 
blot analysis demonstrated clear decreases in GLI1 levels 
in IPI-926 treated tumors consistent with inhibition of 
canonical HH signaling (Figure 4B). As predicted, BMP4 
levels are highest in SKOV3+CA-MSC tumors. Supporting 
a positive feedback loop between tumor derived HH and 
CA-MSC derived BMP4, there was a 3-fold reduction in 
BMP4 protein levels in SKOV3+CA-MSC tumors treated 
with IPI-926 compared to SKOV3+CA-MSC untreated 
tumors (Figure 4B). Likewise, SHH protein levels were 
also reduced (4-fold) in SKOV3+CA-MSC tumors treated 
with IPI-926 compared to untreated tumors. 
Histologic analysis of paraffin embedded tumors 
demonstrated significant differences in the amount of 
stroma in CA-MSC containing tumors (~17 fold increase 
compared to SKOV3 alone tumors) (Figure 4C, 4D). 
This was also observed to a lesser extent with A-MSC 
containing tumors (~5 fold increase). For CA-MSC 
containing tumors, treatment with IPI-926 significantly 
reduced the amount of tumor stroma (Figure 4C, 4D). This 
suggests that HH signaling affects MSC contribution to 
tumor stromal elements.
HH inhibition blocks cA-Msc mediated increase 
in cancer stem cell-like cell percentage
We previously demonstrated that CA-MSCs (and to 
a lesser extent A-MSCs) increase the percentage of ALDH+ 
cancer stem cell-like cells (CSCs) [14, 28]. Evaluation of 
the tumor xenografts above demonstrated that, consistent 
with previous results, there is a significant increase in 
the percentage of ALDH+ cells in the SKOV3+CA-MSC 
tumors compared to SKOV3 alone tumors. This increase in 
ALDH+ cells is completely blocked with IPI-926 treatment 
(Figure 4E). SKOV3+A-MSC tumors also demonstrate a 
modest increase in the percentage of ALDH+ cells which 
is blocked with IPI-926 treatment (Figure 4E). IPI-926 
treated SKOV3 alone tumors demonstrated no statistically 
significant change in the percentage of ALDH+ cells. The 
increase in ALDH+ cells is not primarily related to ALDH+ 
MSCs; when dsRed labeled MSCs were co-grown with 
SKOV3 cells, dsRed+ cells represented ~1.2% of all 
ALDH+ cells thus MSC are not significantly impacting 
the observed differences in ALDH+ cells between groups 
(Supplemental Figure 3C). 
HH inhibition blocks cA-Msc induced 
chemotherapy resistance in ovarian tumor cells 
in vitro and in vivo
Given CA-MSCs can differentiate into distinct 
stromal cells (such as cancer associated fibroblasts and 
adipocytes) which promote chemotherapy resistance, 
and CA-MSCs increase ALDH+ CSCs which are 
chemotherapy resistant [28], we hypothesized that 
CA-MSCs would significantly enhance ovarian tumor 
chemotherapy resistance. We therefore investigated 
the role of CA-MSCs and the tumor/stromal HH/
BMP4 signaling loop in resistance to platinum based 
chemotherapy, the core of ovarian cancer therapy. We 
treated GFP-labeled CAOV-3 cells grown in (i) direct co-
culture with CA-MSCs or (ii) in single culture at equal 
densities and treated for 48 hours with increasing amounts 
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Figure 4: HH inhibition blocks cA-Msc mediated tumor growth promotion and stromal deposition. A. Tumor growth 
curves of SKOV3 ovarian tumor cells ± CA-MSCs treated with and without IPI-926 demonstrating HH inhibition blocks CA-MSC-mediated 
increases in tumor growth. b. Western blot analysis of GLI1, SHH and BMP4 protein levels in SKOV3+CA-MSC and SKOV3+A-MSC 
tumors ± IPI-926 treatment confirm on-target effects of HH inhibition and subsequent decreases in BMP4 and SHH. c. Representative 
H&E stains of tumors: SKOV3, SKOV3+A-MSC or SKOV3+CA-MSC ± IPI-926 illustrating IPI-926 blocks MSC-mediated increases in 
stroma. d. Quantification of stroma in tumors (4 tumors per group, 8 low power sections per tumor). e. Percent ALDH+ cells from SKOV3 
± CA-MSCs or A-MSCs ± IPI-926 xenografts demonstrating IPI-926 blocks the CA-MSC-mediated increase in ALDH+ cells (each scatter 
plot represents an independently analyzed tumor, at least three tumors per group). Error bars=standard error of the mean.
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of cisplatin. Viable cells were analyzed with FACS to 
distinguish GFP-labeled cancer cells from CA-MSCs. 
Co-culture of CAOV-3 cells with CA-MSCs, compared 
to CAOV-3 cells alone, resulted in 3-9 fold increases 
in tumor cell viability in response to cisplatin (Figure 
5A). Addition of IPI-926 drastically decreased CA-
MSC-mediated CAOV-3 cisplatin resistance while not 
significantly altering the efficacy of cisplatin in CAOV-3 
cells grown in single culture (Figure 5A). In contrast, CA-
MSCs grown in single culture demonstrated significant 
resistance to even high doses of chemotherapy (Figure 
5B). The sensitivity of CA-MSCs to cisplatin was not 
significantly altered by co-culture with CAOV-3 cells or 
the addition of IPI-926 (Figure 5B). Interestingly, a modest 
decrease in CA-MSCs was seen with IPI-926 + cisplatin 
in CA-MSC/CAOV-3 co-culture. The ability of IPI-926 
to block CA-MSC-mediated chemotherapy resistance was 
also replicated using co-culture of CA-MSCs and GFP-
labeled PEO-1 and Hey1 ovarian cancer cell lines— lines 
which express both SHH and IHH (Supplemental Figure 4 
and data not shown).
We next determined if the same effect on 
chemotherapy resistance was observed in vivo. CAOV-
3 cells labeled with luciferase were grown ±CA-MSCs 
in the bilateral axilla of NOD/SCID mice and treated 
with cisplatin (1mg/kg weekly for 3 weeks) or vehicle 
control. As expected, cisplatin significantly reduced the 
growth of CAOV-3 tumors (Figure 5C).Once again the 
addition of CA-MSCs to CAOV-3 tumors significantly 
increased growth relative to CAOV-3 cells grown alone. 
Importantly, in the presence of CA-MSCs, CAOV-3 
cells no longer demonstrated a significant response to 
cisplatin (Figure 5C). In fact CAOV-3/CA-MSC tumors 
treated with cisplatin demonstrated greater growth 
than untreated CAOV-3 cells grown alone (Figure 5C). 
To ensure changes in tumor volume were not due to 
overgrowth of the CA-MSC cells, bioluminescence data 
was also captured to assess the luciferase labeled CAOV-3 
fraction. Bioluminescence measurements were consistent 
with tumor volume measurement indicating the change in 
tumor size corresponds with change in tumor cell volume 
(Supplemental Figure 5A). 
To assess the impact of HH inhibition on CA-
MSC-mediated chemotherapy resistance, CAOV-3 cells 
± CA-MSCs in were injected into the bilateral axilla of 
NOD/SCID mice. Tumors were treated with cisplatin as 
described above (starting on day 7) ± daily treatment of 
IPI-926 (20mg/kg/day starting on day 5 after injection 
and continuing for 21 days). Cisplatin treated CAOV-3/
CA-MSC tumors grew significantly faster than cisplatin 
treated CAOV-3 alone tumors. The addition of IPI-926 
to cisplatin treatment of CAOV-3 alone tumors had no 
impact on tumor growth. However, IPI-926 with cisplatin 
lead to a striking decrease in the growth of CAOV-3/
CA-MSC tumors with 2 out of 8 tumors failing to initiate 
(engraftment rates were 100% in all other groups) (Figure 
5D). 
To assess the impact of HH inhibition on established 
tumors, once tumors from mice bearing CAOV-3/CA-
MSC tumors treated with cisplatin reached ~300mm3 in 
volume, mice were randomized and then retreated with 
(i) cisplatin alone (1mg/kg weekly for up to 3 weeks) 
or (ii) cisplatin with IPI-926 (starting three days prior 
to the first cisplatin dose). Cisplatin treatment alone had 
no impact on tumor growth indicating chemotherapy 
resistance. In contrast, retreatment with cisplatin + IPI-
926 lead to not only cessation in tumor growth but to 
tumor regression while tumors in mice retreated with 
cisplatin alone continued to grow rapidly (Figure 5E). This 
demonstrates that not only does blocking HH signaling 
lead to prevention of CA-MSC mediated chemotherapy 
resistance when tumors are small or just starting to 
engraft, but also significantly impacts tumors which have 
been firmly established and have been previously treated 
with chemotherapy.
Analysis of tumor ALDH expression was consistent 
with our previous findings with SKOV3 xenografts, 
demonstrating increases in the percentage of ALDH+ 
cells in CA-MSC containing tumors which is decreased 
in tumors treated with IPI-926 (Figure 5F). Histologic 
analysis demonstrates that CA-MSC containing tumors 
have significantly higher microvessel density (as 
determined through quantification of human and mouse 
CD31 positive vessels per high power field) (Figure 5G, 
5Hii). IPI-926 treatment blocked this increase in blood 
vessel density. Likewise, CA-MSC containing tumors had 
significantly more alpha-smooth muscle actin (αSMA) 
positive cells than CAOV-3 cells alone and this effect was 
decreased with IPI-926 treatment (Figure 5G, 5Hi). Co-
staining with an anti-human mitochondrial antibody (anti-
hMt) demonstrated that the majority of αSMA positive 
cells within CA-MSC-containing tumors are of human 
origin and therefore likely represent differentiated CA-
MSCs. αSMA positive cells within the CAOV-3 alone 
tumors did not co-stain with anti-hMt and are therefore 
likely of murine origin. Also of note, the staining pattern 
of αSMA in CAOV-3 alone tumors is largely perivascular 
and likely to represent vascular associated pericytes 
whereas αSMA positive cells in the CA-MSC containing 
tumors, in addition to being found perivascularly, were 
also present in large extra-vascular bands consistent with 
activated fibroblasts. This is consistent with our findings 
in SKOV3 xenografts which demonstrated clear, gross 
changes in the amount of tumor stroma in CA-MSC 
containing tumors which is reversed with HH inhibition. 
Collectively, our results demonstrate that HH 
pathway inhibition prevents CA-MSC-mediated tumor 
growth promotion and enhancement of chemotherapy 
resistance. This points to a tumor/CA-MSC HH/BMP4 
signaling loop as a critical mediator of the pro-tumorigenic 
effects of CA-MSCs.
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Figure 5: cA-Mscs promote chemotherapy resistance which can be reversed with HH inhibition. A.-b. In vitro co-culture 
of GFP-CAOV-3 tumor cells ± CA-MSCs treated with cisplatin ± IPI-926, A. co-culture with CA-MSCs enhance tumor cell platinum-
resistance and is reversed with IPI-926, graph represents % viable GFP-CAOV-3 cells normalized to 0ug/ml cisplatin group. b. CA-MSCs 
demonstrate cisplatin-resistance is not significantly altered by co-culture with tumor cells or co-treatment with cisplatin + IPI-926, graph 
represents % viable CA-MSCs normalized to 0ug/ml cisplatin group. c. Growth curve of CAOV-3 and CAOV-3/CA-MSC xenografts 
treated ± cisplatin demonstrating CA-MSCs promote platinum-resistance in vivo d. Growth curve of CAOV-3 and CAOV-3/CA-MSC 
xenografts treated with cisplatin ± IPI-926 demonstrating IPI-926 prevents CA-MSC-mediated platinum-resistance. e. Growth curve of 
CAOV-3/CA-MSC xenografts retreated with cisplatin ±IPI-926 starting on day 53 demonstrating IPI-926 reverses chemotherapy resistance 
in established tumors. F. Percent ALDH+ cells from CAOV-3±CA-MSCs xenografts treated with cisplatin±IPI-926 demonstrating IPI-926 
blocks CA-MSC-mediated increases in ALDH+ cells. G. IF of CAOV-3 and CAOV-3/CA-MSC xenografts with anti-alpha smooth muscle 
actin (αSMA) (green), anti-αSMA (red) /anti-human mitochondrial antibody (hMT-green) demonstrating increased human stroma in CA-
MSC-containing tumors and IHC of anti-CD31 (human/mouse). H. i) Quantification of αSMA per high power field (HPF) demonstrating 
IPI-926 blocks CA-MSC-mediated increases in fibroblasts ii) Quantification of microvessel density per HPF illustrating IPI-926 blocks 
CA-MSC-mediated increase in microvessel density. Error bars=standard error of the mean.
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dIscussIon
Increased HH signaling is correlated with poor 
outcomes in ovarian cancer [19]. Further, HH signaling 
is increased at the time of disease recurrence indicating 
the importance of this pathway in ovarian cancer [20]. 
Previous work indicates that HH acts primarily on the 
stroma [18]. However, which cells in the stroma HH acts 
upon was unclear. We now show that CA-MSCs are a 
critical target for stromal HH activation. HH activation of 
CA-MSCs results in the previously reported increased CA-
MSC expression of BMP4 [14]. BMP4 in turn increases 
tumor HH expression, thus creating a positive feedback 
loop (Figure 6). We find this loop is critical to CA-
MSC-mediated increases in tumor growth and promotes 
chemotherapy resistance associated with increases in 
ALDH+ ovarian cancer stem-like cells. Interruption of this 
signaling loop with pharmacologic HH inhibition prevents 
the growth-promoting effects of CA-MSCs in vivo, 
reverses chemotherapy resistance and normalizes CSC 
percentages, indicating the importance of HH signaling 
to the pro-tumorigenic function of CA-MSCs. Our work 
is consistent with studies indicating HH inhibition can 
overcome stromal mediated chemotherapy resistance [3]. 
These prior studies found HH inhibition could overcome 
taxane but not platinum resistance. Platinum is the 
cornerstone of ovarian cancer therapy. Our work shows 
that HH inhibition can overcome platinum resistance even 
in well-established tumors.
Incorporating cA-Msc in tumor xenografts
Our work is unique from the prior studies of HH 
as CA-MSCs create a ‘humanized’ tumor stroma. Unlike 
most ovarian cancer cell line xenografts and later passage 
PDX, CA-MSC containing tumors have a robust human 
stroma more analogous to that seen in patient tumors. 
This is important as we observed minimal effectiveness 
of HH inhibition, either alone or in combination with 
chemotherapy, in the standard human cell line xenograft 
model. However we observed robust response in tumors 
with humanized stroma. This indicates the importance of 
studying therapeutics in the context of a human stroma. 
We previously demonstrated human fibroblast, 
adipocyte and osteoblast mRNA expression in xenografts 
containing human CA-MSCs. We now use IHC analysis 
with anti-human mitochondria antibodies to confirm CA-
MSC containing xenografts have a predominantly human 
tumor stroma. CA-MSC containing xenografts have 
increased numbers of αSMA+ activated myofibroblasts 
which is prevented by HH inhibition. Additional studies 
will be necessary to determine the mechanism whereby 
HH inhibition reverses CA-MSC mediated stromal 
formation. It is interesting to note that CA-MSCs by 
themselves are highly chemotherapy resistant. Thus 
CA-MSCs are likely preserved following chemotherapy 
and could support the expansion and ultimately the drug 
resistance of residual cancer cells. 
Figure 6: schematic of ovarian tumor cell:cA-Msc hedgehog:bMP4 feed forward loop. Ovarian tumor derived HH induces 
increased expression of BMP4 in CA-MSCs. CA-MSC derived BMP4 feeds back and induces increased expression of tumor derived HH. 
Blocking this signaling loop with the HH inhibitor IPI-926 prevents CA-MSC mediated increases in cancer stem cell-like cells, tumor 
growth, tumor stroma, tumor vasculature and chemotherapy resistance.
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Hedgehog in malignancy
HH inhibition is an effective therapeutic approach 
in both basal cell carcinomas and meningiomas [29-31]. 
HH is an important tumor/stroma signaling component 
in several solid tumors including prostate, colon and 
pancreatic cancers [18, 32-35]. However, HH does not 
promote growth in all tumor models. Studies in bladder 
cancer suggest that HH:BMP tumor/stromal signaling 
restricts cancer growth [23]. Similarly, recent work in a 
pancreatic cancer model demonstrates a tumor growth 
inhibitory role for HH signaling with concurrent increases 
in tumor stromal elements [33]. Indeed, recent trials 
in colon and pancreatic cancer demonstrated no benefit 
and in one pancreatic trial, a possible trend toward harm 
with hedgehog inhibition [22, 36, 37]. In contrast, a HH 
inhibitor maintenance trial in ovarian cancer demonstrated 
no evidence of detriment [38] with a trend towards 
improvement in progression free survival. One potential 
explanation for the differences observed for HH inhibitors 
in ovarian cancer vs. colon, bladder, and pancreatic 
cancers is the developmental origin of the distinct tissues; 
embryologically, ovarian/fallopian tube epithelium is 
mesodermal in origin. In contrast pancreatic, colon, and 
bladder epithelial cells are endodermal in origin. During 
development, HH signaling has widely contrasting tissue-
specific functions therefore it would not be surprising that 
HH signaling may act in a completely different manner 
in cells derived from different primary germ layers [39]. 
Further highlighting the complexity of HH signaling, 
we demonstrate that both tumor derived SHH and IHH 
form a signaling loop with CA-MSC-derived BMP4. 
Interestingly, in vitro SMO inhibition with IPI-926 more 
effectively disrupted the SHH/BMP4 loop as compared to 
the IHH/BMP4 loop. Additional work will be necessary to 
determine if this relates to currently undefined differences 
in SHH and IHH signaling or alternate pathways 
promoting tumor cell IHH secretion. 
As noted above, HH inhibitors have not 
demonstrated significant clinical activity as single agents 
in ovarian cancer [38]. It has been suggested this trial 
failed as it did not select patients based on tumor HH 
expression [40]; the rate of HH activation in ovarian 
cancers (25-70%) remains controversial [19, 40, 41]. 
Our study suggests greatest potential clinical benefit in 
combining HH inhibition with chemotherapy. Indeed 
targeting HH may be a strategy to reverse platinum-
resistance, an inevitable and deadly step in the progression 
of ovarian cancer.
bMP4 and ovarian cancer
While a majority of the studies presented here, due 
to availability of clinically relevant inhibitors, focused 
on HH inhibition, BMP4 is also a critical component of 
this signaling loop. A BMP4 blocking antibody mimicked 
HH inhibition in vitro. Several studies have supported a 
critical role for BMP4 in ovarian cancer. BMP4 promotes 
migration and metastasis in ovarian cancer [42] and BMP4 
stimulation of ovarian cancer cells can activate ID3 proto-
oncogene expression [43]. We previously demonstrated, 
and confirmed here, that BMP signals from CA-MSCs 
increase the number of ALDH+ CSCs. We have also 
recently reported BMP2 as a regulator of CSC division 
increasing the proportion of ALDH+ cells [44]. Consistent 
with prior studies [45] [14], our data also demonstrate a 
modest increase in ALDH+ tumor cells after co-growth 
with normal adipose-derived MSCs (which at baseline 
have significantly lower levels of BMP4 compared to CA-
MSCs). This may be due to alternate signaling pathways 
such as the IL6/CXCL7 loop reported in breast cancer 
[45]. Alternatively, this may be due to the development 
of a CA-MSC-like expression profile (with increasing 
levels of BMP2 and 4) in normal adipose-derived MSCs 
after long periods of tumor stimulation. Indeed, our 
previous work demonstrated tumor cell conditioning over 
time leads to changes in the overall expression profile of 
normal tissue MSCs yielding increases in BMP family 
proteins [14]. Further, IPI-926 blocks the normal MSC-
mediated increase of ALDH+ tumor cells arguing for the 
development of a tumor:MSC HH:BMP signaling loop 
over time in normal MSCs. 
While clearly important in ovarian cancer, effective 
clinical targeting of the BMP pathway has proven 
challenging. The identification of HH as a vital modulator 
of stromal BMP4 production provides a novel method to 
target BMP-associated tumorigenesis.
Mscs and ovarian cancer
While controversy remains regarding the role 
of MSCs and cancer in general, numerous studies in 
ovarian cancer report a pro-tumorigenic role of MSCs. 
MSCs can directly impact the cancer cells to increase 
the growth of cancer stem cell-like cells [14], promote 
an epithelial mesenchymal transition [46], and increase 
resistance to apoptosis [47]. MSCs can also promote 
cancer cell chemotherapy resistance, even in the setting 
of hyperthermic therapy [48]. MSC are also reported to 
promote ovarian cancer invasive capacity and broadly 
impact the transcriptional profile of cancer cells to create 
a pro-metastatic phenotype [48, 49]. Interestingly, the 
impact of MSCs on cancer cells can be both via cytokine 
signaling as described here, and the exchange of cellular 
materials via exosomes [50, 51]. Similarly, MSCs can 
impact the host cells in the tumor microenvironment 
promoting ovarian cancer growth via increased 
angiogenesis [52] and suppression of the anti-tumor 
immune responses [53]. Taken together this data strongly 
supports MSCs as a therapeutic target in ovarian cancer. 
Given HH inhibition in vivo completely eliminated many 
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of the pro-tumorigenic effects of CA-MSCs including 
increased angiogenesis, chemotherapy resistance, and 
increased tumor ‘stemness’ HH signaling may be a master 
regulator of CA-MSC function in ovarian cancer.
conclusIon
In summary, the identification of a signaling loop 
with tumor derived HH and CA-MSC derived BMP4 
adds further support to the importance of the tumor 
microenvironment and stromal signaling. Our findings 
help to elucidate the mechanism of CA-MSCs pro-
tumorigenic functions. We demonstrate the critical 
importance of evaluating stromal targeted therapeutics 
in the presence of a human tumor stroma. Finally, these 
studies add to growing literature supporting the clinical 
use of HH inhibitors in ovarian cancer particularly in 
combination with chemotherapy and may specifically 
help revert platinum resistant disease to platinum sensitive 
disease.
MAterIAls And MetHods
tissue harvesting and culture
Patients samples were obtained in accordance with 
a protocol approved by the University of Michigan’s 
IRB (IRB no HUM0009149). Tissue was processed for 
RNA isolation as previously described [54]. MSCs were 
isolated as previously described [14]. Briefly, to isolate 
CA-MSCs primary patient derived tumor tissue was plated 
in supplemented MEBM media and MSCs were selected 
for plastic adherence. CA-MSCs were characterized 
by cell surface marker expression (positive for CD105, 
CD90, CD73, CD44; negative for CD34, CD24, CD45) 
and their ability to differentiate into adipocytes, osteocytes 
or fibroblasts (following guidelines presented by The 
International Society for Cellular Therapy on the minimal 
criteria for defining multipotent mesenchymal stem 
cells[15]). A summary of CA-MSC cell surface marker 
expression and differentiation is provided in Supplemental 
Figure 6. Adipocyte and osteocyte differentiation was 
stimulated using differentiation media from StemCell 
technologies, (Vancover, BC). Fibroblast/myofibroblast 
differentiation was performed through prolonged indirect 
co-culture with ovarian tumor cells. Normal healthy 
donor-derived MSCs were purchased (for adipose MSCs) 
(Invitrogen, Grand Island, NY) or derived from normal 
omental or normal ovary surgical samples (using the same 
procedure as above for CA-MSC isolation from tumor 
tissue). Adipose, normal ovary and patient derived CA-
MSCs were maintained in culture as previously described 
[14]. Mesenchymal stem cells were used at passage 8 
or below. Ovarian cancer cell lines SKOV3, CAOV-3, 
COV318, Hey1 and PEO1 were obtained from ATCC and 
cultured in RPMI supplemented with 10% heat-inactivated 
FBS and 1% penicillin/streptomycin (SKOV3, Hey1) and 
DMEM supplemented with 10% heat-inactivated FBS and 
1% penicillin/streptomycin (CAOV-3, COV318, PEO1). 
Gli1lacZ mice
Gli1lacZ reporter mice were treated for 5days with 
anti-mouse CD3e (clone 2c-11, Ebioscience San Diego, 
CA) antibody to reduce immune rejection of tumor 
cells. ID8 xenografts were created by injecting 10x106 
cells into the bilateral flanks of treated animals. ID8 
xenograft tissue was obtained at time of sacrifice and 
B-Galactosidase staining was performed on tissues fixed 
in 4% PFA and embedded in OCT for cryosectioning 
[25]. Normal ovarian tissue was obtained from non-T cell 
depleted animals and processed as above. Quantification 
of B-Galactosidase staining was performed using ImageJ 
thresholding analysis [55]. Three independent sections of 
tumor and non-tumor stroma were used for quantification.
Quantitative real-time Pcr
RNA was isolated with the RNeasy Mini 
Kit (Qiagen, Hilden, Germany) and on-column 
DNase treatment (Qiagen, Hilden, Germany). RNA 
concentration was determined with NanoDrop ND-1000 
Spectrophotometer. cDNA was synthesized with the 
SuperScript III First-Strand Synthesis System for RT-PCR 
(Invitrogen, Grand Island, NY) as previously described 
[56]. SYBR green-based RT-PCR was performed using 
the 7900HT Sequence Detection System (Applied 
Biosystems, Foster City, California) and respective 
primers. The comparative Ct method was used for data 
analysis, HPRT or GAPDH were used as the comparator 
genes. 
Immunoblotting
Portions of whole tumor or cell pellets were 
homogenized in RIPA buffer (Pierce, Rockford, IL) with 
complete protease inhibitor (Roche, Basel, Switzerland). 
Insoluble material was removed by centrifugation at 
16,000g at 4oC for 15mins. Protein concentrations were 
determined using the Bradford Protein Assay Kit (Bio-
Rad, Hercules,CA). Equal amounts of protein were 
separated on 4-12% NuPAGE SDS gel (Invitrogen, Grand 
Island, NY) and transferred onto a PVDF or nitrocellulose 
membrane. Antibodies for western blot analysis include 
anti-BMP4 (1:1000 dilution, Abcam, Cambridge, 
England), anti-SHH (1:500, 5E1, Developmental Studies 
Hybridoma Bank, Iowa City, IA), anti-Gli1 (1:500, PCRP-
GLI1-1A1, Developmental Studies Hybridoma Bank, 
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Iowa City, IA) and anti-B-actin (1:10,000 dilution, Sigma-
Aldrich, St. Louis, MO). Bands were visualized using the 
ECL Kit (Pierce, Rockford, IL). 
In vitro sHH or tcM treatment of Mscs
Adipose, normal ovary and CA-MSCs plated at 
1x105 cells/6well in serum free supplemented MEBM 
media were treated with recombinant SHH (10-100ng/ml) 
(R&D systems, Pittsburg, PA) for 24hrs then processed 
for qRT-PCR as described above. For TCM, media was 
collected from tumor cell lines grown to 60% confluence 
after 3 days and centrifuged for 15min at 3500rpm to 
remove cellular debris. MSCs were treated with TCM ± 
IPI-926 (10nM) for 3 days then cells were processed for 
qRT-PCR or immunoblotting. 
In vitro bMP4 treatment of tumor cells
SKOV3, CAOV-3 and COV318 cells were plated 
(2x105 cells/6 well dish) in serum-free media treated with 
200ng/ml recombinant BMP4 (R&Dsystems, Pittsburg, 
PA) for 16 and 48hours. Cells were then processed for RT-
PCR or immunoblotting.
cA-Msc/tumor cell co-culture
SKOV3, CAOV-3, or COV318 were grown in co-
culture with CA-MSCs using 24mm polystyrene transwell 
inserts, 0.4um pore (Sigma Aldrich, St. Louis, MO). CA-
MSCs (5x104cells) were seeded onto the top chamber in 
1.5ml supplemented MEBM media and tumor cells (5x104 
cells) were seeded into the lower chamber in 2.5ml RPMI 
or DMEM ± 20nM IPI-926 or LDE225 (APExBIO) or 
the anti-BMP4 blocking antibody (R&D systems) for 5 
days. CA-MSCs and tumor cells grown alone were used 
as controls. 
In vivo mouse Msc/tumor xenografts 
Xenografts containing SKOV3 cells alone (1x106 
cells), SKOV3 + A-MSCs (0.5x106 cells each) and 
SKOV3 + CA-MSCs (0.5x106 cells each) with growth 
factor reduced matrigel (BD Biosciences, San Jose, CA) 
were injected into the bilateral axilla of NOD-SCID 
mice. After 5 days (to allow for tumor engraftment), half 
of the mice were treated with IPI-926 (Active Biochem, 
Hamburg, Germany) (20mg/kg daily via IP injection for 
21 days as previously described by Lee et al. [57]). Mice 
were sacrificed when tumor burden exceeded 1500mm3. 
Tumor volume was calculated using the modified ellipsoid 
formula (L*W2)/2. Five mice with bilateral axillary 
xenografts were used per treatment group (n = 10 tumors 
per group). Two additional mice were injected with dsRed 
MSC/SKOV3 xenografts to serve as controls for FACS 
analysis below. NOD-SCID mice were maintained in 
accordance with institutional policies and all studies were 
performed with approval of the University Committee on 
Use and Care of Animals of the University of Michigan.
In vitro chemotherapy resistance assays
CAOV-3, PEO1 or Hey1 cells labeled with GFP 
via lentiviral transduction were grown in co-culture with 
CA-MSCs in a 1:1 ratio with a total of 20,000 cells/24 
well dish or in single culture with 20,000 cells/well and 
treated with cisplatin ± IPI-926 (20nM) for 24-48 hours. 
The number of viable GFP-tumor cells and CA-MSCs was 
analyzed via FACS using propidium iodide for viability 
stain and gating on GFP positive cells (for tumor cell 
analysis) or GFP negative cells (for CA-MSC analysis). 
In vivo chemotherapy resistance
Xenografts containing luciferase labeled CAOV-
3 cells alone (1x106 cells), CAOV-3/A-MSCs (0.5x106 
cells each) and CAOV-3/CA-MSCs (0.5x106 cells each) 
with growth factor reduced matrigel were injected into 
the bilateral axilla of NOD-SCID mice. After 7 days, half 
of the mice were treated with cisplatin (1mg/kg weekly 
x 3 weeks). Bioluminescence was measured at day 40. 
Tumor volume measurement and euthanasia criteria 
were followed as above. Five mice with bilateral axillary 
xenografts were used per treatment group (n = 10 tumors 
per group).
The experiment was repeated with CAOV-3 cells 
alone and CAOV-3/CA-MSCs. After 5 days, half of 
the mice were treated with IPI-926 (20mg/kg daily via 
IP injection for 21 days). All mice received cisplatin 
treatment (1mg/kg weekly x 3 weeks starting on day 7 
after injection). When the CAOV-3/CA-MSC cisplatin 
treated tumors reached ~300mm3, half of the mice were 
retreated with cisplatin (1mg/kg weekly for up to 3 weeks) 
and half were retreated with cisplatin + IPI-926 (20mg/
kg daily until time of sacrifice). Five mice with bilateral 
axillary xenografts were used per treatment group (n = 
10 tumors per group) except in the CAOV-3/CA-MSC 
groups which contained 4 mice with bilateral tumors (n 
= 8 tumors). 
Immunohistochemistry
Tumors were cryosectioned or paraffin embedded. 
Paraffin-embedded tissue was H&E stained at the ULAM 
Pathology Cores for Animal Research at the University of 
Michigan and stroma quantified per low-power field (10x). 
Cryosectioned tumors were fixed and stained with anti-
CD31 antibody (Dako) or permeablized and stained with 
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anti-αSMA antibody- Cy3 (Abcam) and co-stained with 
mouse anti-human mitochondrial antibody (Life tech) with 
goat anti-mouse-alexa 488 secondary. CD31 + cells were 
counted to determine microvessel density per hpf (40x). 
Anti-αSMA staining was quantified by determining the 
area of positive staining per hpf (40x). 10 sections from 3 
tumors per treatment group were analyzed [58]. 
FAcs
Xenograft single cell suspensions were analyzed 
for ALDH expressing cells with the Aldehyde 
Dehydrogenase-Based Cell Detection Kit as previously 
described [28] (Stemcell Technologies, Vancouver, 
Canada). FACS gating was based on live cells (via 
DAPI) with DEAB control for each sample. At least 3 
independent tumors were used for each analysis except 
for the CAOV-3/CA-MSC+Cis+IPI-926 group in which 
two tumors were analyzed due to low tumor burden in 
this group. Flow cytometric analysis was performed on a 
BD Biosciences FACSCalibur through the University of 
Michigan Flow Cytometry Core.
statistics
All in vitro experiments were repeated 
independently at least three times with triplicate samples 
in each experiment unless otherwise stated. Statistical 
significance was evaluated using a 2-sided student’s T-test. 
For all experiments, α = 0.05. For animal studies, n = 10 
per group based on final tumor volume of control animals 
of ~1000mm3 with an expected standard deviation of 30%. 
Non-linear regression analysis of tumor growth over time 
was performed for each group and curves compared to 
determine statistical significance. In all Figures, error bars 
represent standard error of the mean of composite values 
from independent experiments. 
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